APP Abraxane launch
Executive Summary
American Pharmaceutical Partners' nanoparticle albumin-bound paclitaxel formulation Abraxane is scheduled to launch Feb. 8. The metastatic breast cancer treatment, which cleared FDA Jan. 7, is likely to be priced at a premium to Bristol-Myers Squibb's Taxol and Sanofi-Aventis' Taxotere based on safety and efficacy data...